← Back to Clinical Trials
Recruiting NCT07239258

NCT07239258 The Effects of Mir Shakeel Teleintegrated Therapy Plan in Patients Undergoing Total Knee Arthroplasty

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07239258
Status Recruiting
Phase
Sponsor Lincoln University College Malaysia
Condition Total Knee Anthroplasty
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2025-11-30
Primary Completion 2026-11-01

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Mir Shakeel Teleintegrated Therapy planConventional Physical Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2025-11-30 with a primary completion date of 2026-11-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized controlled trial aims to evaluate the effectiveness of a newly developed Modified Structured Telerehabilitation Intervention Protocol (MSTITP) compared with conventional in-person physical therapy in patients recovering from Total Knee Arthroplasty (TKA). The study also explores whether a hybrid rehabilitation approach may further optimize patient outcomes. A total of eligible participants aged 50-65 years who have undergone primary TKA will be randomly assigned to one of two groups: Group A (Intervention): Telerehabilitation-based structured exercise program (MSTITP) delivered through digital platforms with remote supervision. Group B (Control): Standard conventional face-to-face physiotherapy in a clinical setting. Both groups will receive rehabilitation programs of equal duration focusing on pain management, range of motion (ROM), muscle strengthening, gait training, and functional mobility. The primary objective is to compare the effectiveness of telerehabilitation and conventional therapy in improving pain, ROM, and gait performance. Secondary objectives include evaluation of exercise adherence, kinesiophobia, functional outcomes, quality of life, and patient satisfaction. Additionally, the study will explore whether integrating telerehabilitation with conventional rehabilitation could provide superior outcomes. Outcome assessments will be conducted using validated tools including pain scales (VAS), goniometric ROM measurements, gait analysis, functional performance tests, and standardized questionnaires for quality of life, exercise adherence, and fear of movement. This study addresses the increasing burden of osteoarthritis and the growing number of TKA procedures in Pakistan. Telerehabilitation may offer a cost-effective, accessible, and scalable rehabilitation model that ensures continuity of care and improved access to physiotherapy services, particularly in resource-limited settings. The findings of this trial are expected to provide evidence for developing standardized, technology-assisted rehabilitation protocols to improve post-TKA recovery outcomes and reduce healthcare burden.

Eligibility Criteria

Inclusion Criteria: * Patients who have underwent a primary unilateral total knee arthroplasty due to osteoarthritis * Able to participate in a rehabilitation program, either telerehabilitation or in-person, and demonstrate sufficient mobility with or without assistive devices (e.g., crutches, walker) as deemed appropriate for post-TKA therapy. * Participants must have reliable access to a smartphone, tablet, or computer with internet connectivity and the ability to engage in video calls. * Willing and able to provide informed consent, and to comply with all study protocols, including scheduled therapy sessions and follow-up assessments. Exclusion Criteria: * Presence of significant comorbidities or complications that could interfere with safe participation in rehabilitation, such as severe cardiovascular disease, or conditions causing significant immobility (e.g., severe osteoarthritis in other joints or Rheumatoid Arthritis. * Previous knee replacement or other significant knee surgeries on the same knee, as this may impact the standardization of rehabilitation outcomes. * Currently enrolled in another physical therapy or rehabilitation trial, or engaging in additional rehabilitation outside the study protocol. * Cognitive impairment or severe visual or hearing impairments that would prevent them from following therapy instructions or engaging with telerehabilitation technology. * Any other conditions or factors that, in the opinion of the investigators, could hinder compliance with the study procedures or put the participant at undue risk.

Contact & Investigator

Central Contact

Dr. Mir Shakeel Ahmad

✉ mirshakeel.phdscholar@lincoln.edu.my

📞 00923224268894

Principal Investigator

Dr. Mir Shakeel Ahmad

PRINCIPAL INVESTIGATOR

Lincoln College University

Frequently Asked Questions

Who can join the NCT07239258 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 65 Years, studying Total Knee Anthroplasty. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07239258 currently recruiting?

Yes, NCT07239258 is actively recruiting participants. Contact the research team at mirshakeel.phdscholar@lincoln.edu.my for enrollment information.

Where is the NCT07239258 trial being conducted?

This trial is being conducted at Lahore, Pakistan.

Who is sponsoring the NCT07239258 clinical trial?

NCT07239258 is sponsored by Lincoln University College Malaysia. The principal investigator is Dr. Mir Shakeel Ahmad at Lincoln College University. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology